Clinical Trial Update: Safety Study of PLX4032 in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 safety study of PLX4032 (vemurafenib) in patients with solid tumors, including malignant melanoma and colorectal cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Malignant Melanoma

Drugs mentioned

• PLX4032 (vemurafenib)

Snippet

Sponsor: Plexxikon | Conditions: Malignant Melanoma, Colorectal Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2017-08-22